HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Volume 20, No. 4, April 2016 – Leading-Edge ONCOLOGY       » Is Colorectal Carcinomas due to 'Bad Luck' or Is It Preventable?       » Cancer of the Cervix — Can It be Prevented?       » Geriatric Oncology - Featuring Dr. Ravindran Kanesvaran, President of the Singapore Society of Oncology (SSO)       » Discovery Paves the Way for Potential Genetics-Guided Precision Medicine for Paediatric Leukaemia Patients       » China-U.S. Team Uses Stem Cells in Cataract Treatment       » ASLAN - Transforming the Treatment for Rare Tumour Types in Asia       » Using Saltidin to Guard Against the Zika Virus      
BIOBOARD - INSIDE INDUSTRY
Otsuka acquires rights to hematological cancer treatment Dacogen® from Eisai
Otsuka Pharmaceutical has entered an agreement with Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd. to acquire rights to the hematological cancer treatment Dacogen® and to an enzyme inhibitor, E7727.

Eisai will receive the following rights from Otsuka.

  1. Exclusive rights to the development and sale of DNA methylation inhibitor Dacogen®, an intravenous formulation of decitabine (generic name), in the U.S., Canada, and Japan in addition to the licensing rights worldwide excluding Mexico. Eisai will retain the rights in Mexico. Janssen Pharmaceutical Companies will retain its worldwide development and commercialization rights (excluding the U.S., Canada, Mexico and Japan).

  2. Patent rights to metabolic enzyme inhibitor E7727, currently in pre-clinical development by Otsuka's U.S. subsidiary Astex Pharmaceuticals, Inc. E7727 is in development together with decitabine to form the combination product ASTX727 (an oral hypomethylating agent), which if approved would become the first oral formulation of decitabine.
Source: Business Wire

Click here for the complete issue.

NEWS CRUNCH  
news World Immunisation Week 2016
news IoT Asia 2016 Delivers Actionable Solutions for a Sustainable IoT Ecosystem in Asia
news Lite-On presents a new Biomedical Research and Development Centre in Singapore
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Animated Introduction to Cancer Biology (Full Documentary)
COLUMNS  

APBN Editorial Calendar 2016
January:
Guest Editorial - Biotechnology In Korea
February:
Guest Editorial - Biomedical Research Governance
March:
Guest Editorial - Life-Saving Opportunities: A Guide to Regenerative Medicine
April:
Leading-Edge ONCOLOGY
May:
Healthcare Systems & Policies in Asia
June:
Medical Devices and Digital Health Technology
July:
Water Technology
August:
Guest Editorial - Antibody Informatics In Japan
September:
Olympics: Evolution of Sports
October:
Respiratory: Seasonal flu viruses
November:
Food Technology
December:
Biomedical Imaging
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» Editorial Enquiries: biotech_edit@wspc.com
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   Ms PoPo Kwok or Ms Sok Ching Lim/td>
Copyright© 2015 World Scientific Publishing Co Pte Ltd  •  Privacy Policy